Section Arrow
KYNB.NASDAQ
- Kyntra Bio Inc
Quotes are at least 15-min delayed:2026/01/10 05:07 EST
Regular Hours
Last
 9.22
-0.28 (-2.95%)
Day High 
9.66 
Prev. Close
9.5 
1-M High
10.4699 
Volume 
18.94K 
Bid
9.2
Ask
9.62
Day Low
9.22 
Open
9.51 
1-M Low
8.3 
Market Cap 
39.28M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 9.01 
20-SMA 8.9 
50-SMA 9.21 
52-W High 21.9375 
52-W Low 4.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
53.33/-6.66
Enterprise Value
112.37M
Balance Sheet
Book Value Per Share
-4.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
29.62M
Operating Revenue Per Share
38.31
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4944+0.11+28.62%-- 
ASBPAspire Biopharma Holdings Inc.0.104+0.0007+0.68%-- 
RVMDRevolution Medicines118.64+11.25+10.48%-- 
ARDXArdelyx7.74+0.74+10.57%-- 
SLSSELLAS Life Sciences Group3.46-0.4-10.36%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe andOthers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.